Daghaghzadeh Hamed, Emami Mohammad Hasan, Karimi Somayeh, Raeisi Mostafa
Isfahan University of Medical Science and Pour Sina Hakim Research Institution, Isfahan, Iran.
J Gastroenterol Hepatol. 2007 Sep;22(9):1399-403. doi: 10.1111/j.1440-1746.2007.05029.x. Epub 2007 Jul 20.
Furazolidone-based regimens for the eradication of Helicobacter pylori are low cost and effective although less tolerable. Our aim was to compare the efficacy and compliance of 1-week furazolidone-based quadruple therapy (furazolidone, amoxicillin, bismuth subcitrate, omeprazole; FABO) with 2-week quadruple therapy using the same drugs.
One hundred and fifty-six consecutive patients with H. pylori related diseases were enrolled in our study. The patients were randomized into two groups of FABO1 and FABO2 groups receiving, 1 or 2 weeks' quadruple H. pylori eradication therapies, respectively, as follows: furazolidone (200 mg twice daily), amoxicillin (1 g twice daily), bismuth (240 mg twice daily) and omeprazole (20 mg twice daily). The chi(2) test was used to compare the efficacy of the therapies.
The per-protocol eradication rate in FABO1 and FABO2 groups were 56/66 (84.8%) and 57/69 (82.6%), respectively. The intention-to-treat eradication rate was 56/78 (71.8%) in FABO1 group and 57/78 (73.1%) in FABO2 group. There was not any significant statistical difference between two groups. A significant decrease in compliance in FABO2 group was seen.
This is an encouraging report showing a therapy with possible success in decreasing the duration of H. pylori infection as well as reaching the eradication rate of 80%.
基于呋喃唑酮的根除幽门螺杆菌方案成本低且有效，尽管耐受性较差。我们的目的是比较基于呋喃唑酮的1周四联疗法（呋喃唑酮、阿莫西林、枸橼酸铋钾、奥美拉唑；FABO）与使用相同药物的2周四联疗法的疗效和依从性。
156例连续的幽门螺杆菌相关疾病患者纳入我们的研究。患者被随机分为FABO1组和FABO2组，分别接受1周或2周的幽门螺杆菌根除四联疗法，如下：呋喃唑酮（每日2次，每次200mg）、阿莫西林（每日2次，每次1g）、铋剂（每日2次，每次240mg）和奥美拉唑（每日2次，每次20mg）。采用卡方检验比较疗法的疗效。
FABO1组和FABO2组的符合方案根除率分别为56/66（84.8%）和57/69（82.6%）。FABO1组的意向性治疗根除率为56/78（71.8%），FABO2组为57/78（73.1%）。两组之间无显著统计学差异。FABO2组的依从性显著降低。
这是一份令人鼓舞的报告，表明一种疗法可能成功缩短幽门螺杆菌感染的持续时间，并达到80%的根除率。
